DrugPatentWatch Database Preview
Patent: 9,949,971
Summary for Patent: 9,949,971
| Title: | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
| Abstract: | Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton\'s tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the .gamma.- and .delta.-isoforms and selective for both .gamma.- and .delta.-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-.delta. inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-.delta. inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer. |
| Inventor(s): | Hamdy; Ahmed (Santa Cruz, CA), Rothbaum; Wayne (Delray Beach, FL), Izumi; Raquel (San Carlos, CA), Lannutti; Brian (Solana Beach, CA), Covey; Todd (San Carlos, CA), Ulrich; Roger (Sammamish, WA), Johnson; Dave (Aptos, CA), Barf; Tjeerd (Ravenstein, NL), Kaptein; Allard (Zaltbommel, NL) |
| Assignee: | Acerta Pharma B.V. (Oss, NL) |
| Application Number: | 15/319,740 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,949,971
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Acerta Pharma B.V. (Oss, NL) | 2034-06-17 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Acerta Pharma B.V. (Oss, NL) | 2034-06-17 | RX | Orphan | search |
| Genentech | GAZYVA | obinutuzumab | INJECTABLE;INJECTION | 125486 | 001 | 2013-11-01 | Start Trial | Acerta Pharma B.V. (Oss, NL) | 2034-06-17 | RX | Orphan | search |
| Glaxo Grp Ltd | ARZERRA | ofatumumab | INJECTABLE; INJECTION | 125326 | 001 | 2009-10-26 | Start Trial | Acerta Pharma B.V. (Oss, NL) | 2034-06-17 | RX | Orphan | search |
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | Start Trial | Acerta Pharma B.V. (Oss, NL) | 2034-06-17 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,949,971
| Country | Patent Number | Publication Date |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015193740 | Apr 21, 2016 |
| World Intellectual Property Organization (WIPO) | 2015193740 | Aug 04, 2016 |
| World Intellectual Property Organization (WIPO) | 2015193740 | Dec 23, 2015 |
| United States of America | 2017136014 | May 18, 2017 |
| United States of America | 2018207154 | Jul 26, 2018 |
| Taiwan | 201613644 | Apr 16, 2016 |
| >Country | >Patent Number | >Publication Date |
